What's new

[PIO] Updated joint statement by ECDC and EMA on additional booster doses of COVID-19 vaccines

29101.jpg





The European Centre for Disease Prevention and Control (ECDC) and the European Medicines Agency (EMA) have updated their public health recommendations on the use of additional booster doses of COVID-19 vaccines for the summer and the upcoming autumn and winter season.

The update of the relevant recommendations comes amidst an increase in the percentage of reported cases of COVID-19 and BA.5 intensive care units (ICUs) in several countries, as reflected in the ECDC Country Overview Report (Country Overview Report: week 26 2022 (europa.eu), and in the context of the emergence of Omicron BA.4 and BA.5 variantsThese data signal that a new wave of COVID-19 disease is accelerating across the European Union/European Economic Area (EU/EEA).

This joint statement is based on an assessment of current epidemiological trends and available scientific evidence. It is therefore preliminary and may change as more data become available.

National Technical Advisory Groups on Vaccination (NITAGs) will ultimately make national decisions on the use of COVID-19 vaccines, taking into account the epidemiological situation in their countries.

Recommendations for additional booster doses of mRNA vaccines

In the context of emerging SARS-CoV-2 virus variants and weakened protection from natural and vaccine-induced immunity, licensed COVID-19 vaccines remain highly effective in preventing hospitalization, severe disease and death from COVID-19 disease. Based on current evidence, public health authorities in EU/EEA countries should consider the following:

  1. Improving vaccination coverage with an initial vaccination schedule as well as a first booster dose in eligible individuals, particularly in population groups at higher risk of severe effects and in countries with lower vaccination coverage of the initial schedule and first booster dose. It is important that efforts to reach these groups continue during the summer months with the vaccines currently available.
  1. People aged 60 years and over and vulnerable groups remain at greatest risk of severe disease. According to mathematical modelling, the availability of an early second booster dose to protect people over 60 years of age carries clear benefits. Therefore, both to prevent severe disease and to ensure the responsiveness of the health system, the provision of the second booster dose should be considered not only for the population aged 80 years and over, but also for adults between 60 and 79 years and for vulnerable population groups regardless of age. Countries should consider rapid development of second booster doses with currently available vaccines. The second booster dose may be administered at least four months after the previous dose, with a focus on people who received the previous booster dose more than 6 months previously. This will be particularly relevant and important in countries where the BA.4/5 wave is starting or has not yet peaked.
  1. The administration of an early second booster dose of currently available vaccines to healthcare workers and people working in long-term care facilities is likely to yield only limited benefits due to limited and rapidly waning protection against infection and transmission. Healthcare workers and staff in long-term care facilities may receive a second booster dose for their own protection if they belong to any age-based priority group or if they belong to medically vulnerable groups. Those residing in long-term care facilities should receive all booster doses in accordance with this Directive.
  1. At present, there is no clear epidemiological evidence to support the administration of a second booster dose to immunocompromised persons under 60 years of age, unless they belong to medically susceptible population groups. The ECDC and EMA will continue to closely monitor vaccine efficacy and epidemiological data and will update recommendations accordingly.
  1. The EMA is working on the possible licensing of adapted vaccines in September. However, given the current epidemiological situation and projections, it is important to use currently available vaccines now and not to wait for the availability of adapted vaccines.
  1. In anticipation of the next expected wave in the autumn and winter period, countries should plan to provide further additional booster doses to be administered to population groups at risk of severe disease (e.g.e.g. people over 60 years of age and medically susceptible groups) in early autumn (provided sufficient time has elapsed since the previous booster dose), possibly combining COVID-19 and influenza vaccination campaigns.
  1. If tailored vaccines show increased neutralization of Omicron variants of concern, indicating potentially higher protection against infection and transmission, consideration should also be given to vaccinating healthcare workers and individuals working in long-term care facilities in the fall/winter to provide direct and indirect protection.

In April 2022, the EMA and ECDC recommended that people over 80 years of age can receive a second booster dose of mRNA vaccines. The two agencies did however note at the time that if there is a resurgence of infections it may be necessary to evaluate giving second booster doses to people aged 60 to 79 years as vulnerable people of any age

As a new wave is currently unfolding in Europe, it is important that public health authorities now consider giving a second booster dose to these population groups.

Currently, more than half of the European Union/European Economic Area (EU/EEA) countries are already recommending and implementing second booster doses of COVID-19 vaccines, mainly in older age groups. However, the relative coverage is still low and uneven between countries, as shown in the ECDC Vaccine Tracker.

ECDC and EMA will continue to closely evaluate vaccine efficacy and epidemiological data and monitor progress in the development of tailored vaccines. Authorities in the EU will also continue to work closely with the World Health Organization (WHO) and international partners on policies related to adapted vaccines.

(AF)
Contents of this article including associated images are owned by PIO
Views & opinions expressed are those of the author and/or PIO

Source

[/P]
 
Back
Top